The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.
There have been significant evidence-based literature updates regarding the management of acute ischemic stroke (AIS) in adult patients; these are discussed in a 2018 guideline update.
The 2016 National Health Interview Survey found that high-impact chronic pain and chronic pain that does not limit major life activities were linked to various physical and mental conditions.